LIQUID FORMULATIONS OF INDACATEROL

1 - 20 . (canceled)

21 . An aqueous pharmaceutical composition comprising:

from about 20 weight percent to 99.9 weight percent water;

indacaterol, or a pharmaceutically acceptable salt thereof, present at a concentration of 10 μg/mL to 2 mg/mL;

glycopyrrolate, or a pharmaceutically acceptable salt thereof, present at a concentration of about 10 μg/mL to 2 mg/mL,

two or more tonicity modifiers; and

a buffer,

wherein the indacaterol is present as a free base or as a pharmaceutically acceptable salt thereof without the presence of maleic acid from a maleate salt in the aqueous pharmaceutical composition, and

wherein the aqueous pharmaceutical composition has a pH from 3 to 5.

22 . The pharmaceutical composition of claim 21 , wherein the indacaterol, or a pharmaceutically acceptable salt thereof, is present at a concentration of 10 μg/mL to 200 μg/mL.

23 . The pharmaceutical composition of claim 21 , wherein one of the two or more tonicity modifiers is present at a concentration of about 100 mM to about 500 mM.

24 . The pharmaceutical composition of claim 21 , wherein one or the two tonicity modifiers is sodium chloride.

25 . The pharmaceutical composition of claim 21 , wherein the buffer comprises an anion selected from the group consisting of acetate, bromide, chloride, citrate, furoate, fumarate, propionate, succinate, sulfate, tartrate, and xinafoate.

26 . The pharmaceutical composition of claim 25 , wherein the anion of the buffer in the aqueous pharmaceutical composition is citrate.

27 . The pharmaceutical composition of claim 21 , wherein the buffer in the aqueous pharmaceutical composition is prepared from a combination of citric acid and sodium hydroxide.

28 . The pharmaceutical composition of claim 21 , wherein the buffer in the aqueous pharmaceutical composition is prepared from a combination of citric acid and trisodium citrate.

29 . The pharmaceutical composition of claim 25 , wherein the anion of the buffer in the aqueous pharmaceutical composition is acetate.

30 . The pharmaceutical composition of claim 21 , wherein the buffer in the aqueous pharmaceutical composition is prepared from a combination of acetic acid and sodium hydroxide.

31 . The pharmaceutical composition of claim 21 , wherein the buffer in the aqueous pharmaceutical composition is prepared from a combination of acetic acid and sodium acetate.

32 . The pharmaceutical composition of claim 25 , wherein the anion of the buffer in the aqueous pharmaceutical composition is tartrate.

33 . The pharmaceutical composition of claim 21 , wherein the aqueous pharmaceutical composition has a pH from 3.5. to 4.5.

34 . The pharmaceutical composition of claim 21 , wherein the glycopyrrolate, or a pharmaceutically acceptable salt thereof, is glycopyrronium bromide.

35 . The pharmaceutical composition of claim 21 , wherein the glycopyrrolate, or a pharmaceutically acceptable salt thereof, is present in the aqueous pharmaceutical composition at a concentration in a range from about 50 μg/mL to about 200 μg/mL.

36 . The pharmaceutical composition of claim 21 , wherein the concentration of the indacaterol in the aqueous pharmaceutical composition is between about 50 μg/mL to about 200 μg/mL; and the concentration of the glycopyrrolate, or a pharmaceutically acceptable salt thereof, in the aqueous pharmaceutical composition is between about 50 μg/mL to about 200 μg/mL.

37 . The pharmaceutical composition of claim 21 , further comprising an inhaled corticosteroid.

38 . The pharmaceutical composition of claim 21 , wherein the aqueous pharmaceutical composition does not comprise ethanol or a cyclodextrin.

39 . A kit comprising

the pharmaceutical composition of claim 21 ; and

a device for aerosolizing the pharmaceutical composition.

40 . The kit of claim 39 , wherein the device is selected from the group consisting of a jet nebulizer and a vibrating mesh nebulizer.